Methods of treating metabolic disease
The invention provides methods for treating metabolic disease in a subject and methods for increasing the expression of ILDR2 in a subject. The invention further provides a method for identifying an agent which modulates expression of an Ildr2 RNA comprising contacting a cell with an agent; determining expression of the Ildr2 RNA in the presence and the absence of the agent; and comparing expression of the Ildr2 RNA in the presence and the absence of the agent, wherein a change in the expression of the Ildr2 RNA in the presence of the agent is indicative of an agent which modulates the level of expression of the RNA.
1. A method of treating hepatic steatosis in a subject, the method comprising administering to the subject a therapeutically effective amount of an adenoviral expression vector comprising a nucleic acid encoding full-length ILDR2, and wherein the subject has metabolic syndrome, type II diabetes, insulin resistance, or is obese, or any combination thereof.
2. A method of decreasing hepatic triglyceride level or hepatic total cholesterol level in a subject, the method comprising administering to the subject a therapeutically effective amount of an adenoviral expression vector comprising a nucleic acid encoding full-length ILDR2.
3. The method of claim 2 , wherein the hepatic triglyceride level or hepatic total cholesterol level is decreased relative to a hepatic triglyceride level or hepatic total cholesterol level in the subject before administrating the therapeutically effective amount of an adenoviral expression vector comprising a nucleic acid encoding full-length ILDR2.
4. The method of claim 1 or 2 , wherein the expression of Ildr2 mRNA or ILDR2 protein is increased in liver tissue.
5. The method of claim 1 or 2 , wherein the expression of Ildr2 mRNA or ILDR2 protein is increased in hepatocytes.
6. The method of claim 1 or 2 , wherein the subject is administered an additional therapy.
7. The method of claim 6 , wherein the additional therapy is a lipid lowering therapy.
8. The method of claim 7 , wherein the lipid lowering therapy is a therapeutic lifestyle change, a HMG-CoA reductase inhibitor, niacin, a fibrate, a cholesterol absorption inhibitor, a MTP inhibitor, or any combination thereof.
9. The method of claim 1 or 2 , wherein expression of ILDR2 protein in the subject is measured using an antibody.
10. The method of claim 9 , wherein the antibody specifically binds to a peptide selected from the group consisting of SEQ ID NOs: 2-9, an ILDR2 protein, or an ILDR2 isoform.
11. The method of claim 1 , wherein the subject has a reduced level of expression of Ildr2 mRNA or ILDR2 protein compared to the level of expression of Ildr2 mRNA or ILDR2 protein in a subject without hepatic steatosis.
12. The method of claim 9 , wherein the level of expression is determined before administrating to the subject the therapeutically effective amount of an adenoviral expression vector comprising a nucleic acid encoding full-length ILDR2.
13. The method of claim 11 , wherein the expression of ILDR2 protein in the subject is measured using an antibody.
14. The method of claim 13 , wherein the antibody specifically binds to a peptide selected from the group consisting of SEQ ID NOs: 2-9, an ILDR2 protein, or an ILDR2 isoform.
15. A method of decreasing liver fat deposits in a subject, the method comprising administering to the subject a therapeutically effective amount of an adenoviral expression vector comprising a nucleic acid encoding full-length ILDR2.